Tag: Biosciences
Caribou Biosciences Announces Pricing of Upsized $125 Million Public Offering –...
BERKELEY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced...
Biotech Executive Beth Thompson-Webb Joins Culture Biosciences’ Board of Directo… –...
BOSTON, July 13, 2023 (GLOBE NEWSWIRE) -- Culture Biosciences has appointed Beth Thompson-Webb, Chief Commercial Officer at Virica Biotech, as...
Aptose Presents Highlights from Clinical Update – Aptose Biosciences (NASDAQ:APT… –...
Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally...
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of...
WALTHAM, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. COGT, a biotechnology company focused on developing precision...
Junshi Biosciences Announces Collaboration with Dr. Reddy’s to Develop and Comme…...
SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) announced a...
Aquyre Biosciences Announces Appointment of F. Samuel Eberts III as CEO...
Aquyre Biosciences, Inc. today announced the appointment of F. Samuel Eberts III as Chief Executive Officer and Chairman of its Board of Directors....
Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine)… –...
- Subjects in Herniorrhaphy Study Dosed- Successful FDA Interactions on Two Pre-clinical Pipeline Products Also DiscussedSAN DIEGO, April 18, 2023 /PRNewswire/ -- Cali...
Nona Biosciences Enters into Collaboration Agreement with ExeVir Bio –...
CAMBRIDGE, Mass., April 5, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited, committed to cutting-edge technology innovation and provider of...
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors t… –...
NEW YORK, March 26, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the...
Brii Biosciences Provides Corporate Update and Reports Full-Year 2022 Financial …...
Company maintains priority focus on clinical programs to develop a novel functional cure for hepatitis B viral (HBV) infection and a potential first-of-its-kind treatment...